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 Research 
 
The experience, satisfaction, and Emergency Department utilization of 
pediatric patients with sickle cell disease during the Covid-19 pandemic 
Alexandra E. Kirsch, St. Christopher's Hospital for Children, alexandra.kirsch@towerhealth.org   




The COVID-19 pandemic has influenced how patients utilize healthcare. This study examines the utilization, experience, 
and satisfaction of patients with Sickle Cell Disease (SCD) in the pediatric Emergency Department (ED) during the 
COVID-19 pandemic compared to the care they had received before the pandemic. The authors surveyed fifty-eight 
participants ages 14 months to 20 years who presented to the ED for a complaint related to their SCD during the 
COVID-19 pandemic. The study analyzed five variables: race, SCD severity, hemoglobin (Hgb) genotype, who 
completed the questionnaire (patient versus parent/guardian), and whether the ED visit resulted in an admission to the 
hospital. Our results suggest that the COVID-19 pandemic significantly affected the decision of some patients as to 
whether and when to go to the ED. African Americans and those with severe disease did not wait longer than usual to 
go to the ED, possibly because these groups are more likely to have more serious and more frequent pain crises. Thus, 
their decision to present to the ED was driven more by their relatively worse symptoms, rather than such external 
factors as the pandemic. However, the pandemic did not significantly affect patients’ satisfaction with their ED visit or 
their baseline SCD symptoms. To our knowledge, this is the first study of how the COVID-19 pandemic has affected 
patients’ utilization of, experience in, and satisfaction with a pediatric hospital ED. 
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There are approximately 100,000 people in the United 
States afflicted with the group of inherited 
hemoglobinopathies known collectively as sickle cell 
disease (SCD).1 The vast majority of patients with SCD are 
of African or Hispanic descent. Nationally, patients with 
SCD account for approximately 200,000 Emergency 
Department (ED) visits annually.2 Patients with SCD may 
suffer from numerous complications including chronic 
pain, progressive multi-system organ damage, retinopathy, 
embolism and stroke, acute chest syndrome, and increased 
susceptibility to life-threatening infections, especially in the 
pediatric population.2-3 Acute pain exacerbation due to a 
vaso-occlusive crisis is the most common reason for 
patients with SCD to visit the ED and often requires 
treatment with parenteral opioid medication.2-4 
 
Patients with SCD who contract SARS-CoV-2 have a 
higher risk of complications, severe disease course, and 
death compared to the general population.5 In a study of 
178 patients with SCD and COVD-19 infection reported 
to the SECURE-SCD registry between March and May 
2020, Panepinto and colleagues found that 90% of patients 
accessed care through an ED, 69% required 
hospitalization, 11% were admitted to an intensive care 
unit, and 7% died.5 Thus, patients with SCD who delay or 
avoid seeking emergency medical care due to the COVID-
19 pandemic may be at an increased risk of adverse 
outcomes. 
 
The National Syndromic Surveillance Program found that 
ED visits decreased 42% overall during the early stages of 
the COVID-19 pandemic.6 Patients with SCD have 
consistently expressed a significant level of dissatisfaction 
regarding the ED care they have received, especially when 
compared to the care that these patients have received 
from their usual physician.7-8 The multifactorial reasons 
that patients with SCD are dissatisfied with ED care 
include, but are not limited to, long wait times that may 
result in treatment delays, lack of communication and co-
management between the ED and patients’ primary 
medical provider, perceived lack of empathy, absence of 
standardized treatment protocols, ED provider attitudes 
and discomfort with acute pain management in this patient 
population, and inadequate analgesic dosing.7-8 The well-
established negative perception of ED care raised the 
question of the COVID-19 pandemic’s impact on the 
decision-making process of patients with SCD. This study 
examines whether and when patients with SCD sought 
ED care and their satisfaction with and experience in the 
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ED during the COVID-19 pandemic compared to the ED 
care that they received before the pandemic. 
 
Very few studies have focused on pediatric patients with 
sickle cell disease and healthcare utilization during the 
COVID-19 pandemic. Tsitsikas and colleagues evaluated 
the strategy of preventing hospitalizations and extended 
hospitalizations in the United Kingdom.9 One study 
surveyed providers at 28 practices to determine how the 
COVID-19 pandemic affected outpatient care of patients 
with SCD.10 Another study assessed the level of anxiety of 
adolescents and young adults with SCD to evaluate the 
correlation between COVID-19 experiences, anxiety 
levels, and painful episodes.11 Finally, one study evaluated 
how the pandemic and stay-at-home orders affected ED 
visits to a tertiary care hospital; although this study 
reviewed all patients presenting to the ED, there was a 
small subset who had sickle cell disease.12 To our 
knowledge, this is the first study to investigate the effect of 
the COVID-19 pandemic on the utilization of, experience 
in, and satisfaction with Emergency Department services 
by pediatric patients with sickle cell disease. 
 
Materials and Methods  
 
Participants 
Potential study participants were identified from patients 
with a diagnosis of SCD who were followed long-term at 
the Marian Anderson Sickle Cell Center at St. 
Christopher’s Hospital for Children. The center maintains 
a database of its patients; the authors mined the database 
to identify patients with SCD who visited the ED for a 
complaint related to their SCD during the COVID-19 
pandemic (February 2020 – March 2021). Potential 
participants were contacted to verify the information, 
ensure that they met the inclusion criteria, and were willing 
to participate in the study. 
 
A total of 58 participants were included in the study. Of 
these, 23 (40%) were female and 35 (60%) were male. The 
ages ranged from 14 months to 20 years (m = 13.8 years, 
SD = 5.98 years). 
 
Most of the patients had sickle cell SS (n = 27; 47%), 
followed by SC (n = 20; 35%), S+ thalassemia, (n = 7, 
12%), S0 thalassemia (n = 2; 3%) and S/HPFH (n = 2; 
3%). The disease was classified as severe if patients had 
more than three hospital admissions in a year, cerebral 
vasculopathy, chronic packed red blood cell transfusions, 
or a history of acute chest syndrome in the last three years. 
Most patients were classified as not severe (n = 40; 69%) 
rather than severe (n = 18; 31%). Most of the participants 
were African American (n = 48; 83%) followed by 
Hispanic (n = 6; 10%) and those who self-identified as 
“other” (n = 4; 7%). Table 1 summarizes the 
demographics of the participants. 
Table 1. Patient Demographics 
 
 Variable n (%) or mean (SD) 
Gendera Female 23 (40%) 
 Male 35 (60%) 
Age in years  13.8 (5.98) 
Hgb Genotype SS 27 ( 47%) 
 SC 20 (35%) 
 S+ thalassemia 7 (12%) 
 S0 thalassemia 2 (3%) 
 S/HPFH 2 (3%) 
Disease Severity Severe 18 (31%) 





 Hispanic 6 (10%) 
 
Other 4 (7%) 
aGender as identified from the electronic medical record.  
bRace was self-identified by the patient and/or parent/guardian 
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Intervention  
Patient responses to their experience in and satisfaction 
with a recent Emergency Department visit were recorded 
using a specifically-designed Likert questionnaire (Table 2). 
Telephone interviews were conducted in lieu of in-person 
interviews due to social distancing and safety measures 
implemented during the COVID-19 pandemic. The 
responses to these seven questions were graded on a 1 to 5 
Likert scale, with 1 signifying strong disagreement and 5 
signifying strong agreement (Table 2). Analysis of 
covariance was performed to compare means. The 
remaining four questions, numbered 8 through 12, were 
open-ended or yes/no questions (Table 3).  For these 
purposes, patient experience is defined as something that 
happened to a patient, or how something happened while 
patient satisfaction refers to patients’ expectations and 
whether they were met. As depicted in Table 2, questions 
4 and 5 relate to patient experience, while the other 
questions relate to patient satisfaction. The data were 
analyzed as a whole and also grouped by five variables: 
race, SCD severity, Hgb genotype, who completed the 
questionnaire (parent/guardian versus patient), and 
whether the ED visit resulted in hospital admission. An 
ED visit that resulted in hospital admission was thought to 
be severe enough to require inpatient management and 
thus was used as a surrogate for the severity of an episode. 
Two-tailed p-values less than 0.05 were considered 
statistically significant. 
 
To provide the context of the patient experience relevant 
to this study, patients with SCD who present to the St. 
Christopher’s Hospital for Children ED are evaluated and 
treated according to a standardized algorithm. For patients 
with SCD and a fever greater than or equal to 38.5 degrees 
Celsius, intravenous access is obtained, an appropriate 
workup is initiated, and broad-spectrum intravenous 
antibiotics are begun within one hour of arrival. For 
patients with SCD and pain, patients are given intravenous 
analgesics within 20 to 30 minutes of registration. The 
treatment algorithms were not changed during the 
COVID pandemic. However, new patient social distancing 
and COVID-related safety measures were implemented 
beginning in April 2020 and remain in place. All patients 
and guardians are briefly interviewed upon arrival to the 
ED to assess COVID-19 risk factors including pertinent 
symptoms, recent travel, exposure to a suspected or 
confirmed COVID-positive patient, and whether there is a 
pending COVID-19 test. All patients and visitors to the 
ED are screened for body temperature. All patients with 
SCD who admitted from the ED to an inpatient bed 





Fifty-eight patients participated in the study. The overall 
results for the first seven Likert-scale questions are 
depicted in Table 4. Most patients reported that their 
decision to go to the Emergency Room was affected by 
the COVID-19 pandemic (n = 38; 62%). The responses to 
question 1 were statistically significant across all groups 
except for race. There were significant differences when 
Table 2. Likert Questionnaire Responses Scored from 
Strongly Disagree (1) to Strongly Agree (5) 
 
 1)  My decision to go to the Emergency Room was 
affected by the COVID pandemic. 
2) I waited longer before going to the Emergency 
Room (vs. before the pandemic).  
3) I tried more medications at home for fever and/or 
pain (vs. before the pandemic). 
4) My experience in the Emergency Room was better 
during the pandemic (vs. before the pandemic). 
5) I got to a room and/or got care faster during the 
pandemic (vs. before the pandemic). 
6) I felt the hospital took the proper COVID-related 
precautions (e.g., staff wore masks, ER was cleaned 
regularly, etc.). 
7) I feel like my Sickle Cell Disease symptoms (pain, 
fever, etc.) are milder now (vs. before the pandemic). 
 
Table 3. Open-Ended and Yes/No Questions 
 
 
8) My answers to one (or more) of the choices above 
are different now than it would have been at the 
beginning of the COVID-19 pandemic. 
  
    If Yes, Question number: __ 
    My score would have been: ___ 
9) My biggest concern about going to the Emergency 
Room was (circle all that apply): 
 
              (a) waiting area   (b) registration                      
(c) other patients   (d) providers   (e) admissions 
10) I was screened for COVID symptoms when I 
arrived at the Emergency Room:  Y / N 
11) I used telemedicine (video or telephone 
appointment) during the pandemic:   Y / N 
      If Yes, how was the experience? ___ 
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patient responses were analyzed by hemoglobin genotype 
(mean = 3.04 for Hgb SS versus a mean = 3.77 for other 
genotypes, p = 0.047), whether the parent/guardian or 
patient completed the questionnaire (mean = 2.72 for 
parents/guardians, mean = 3.75 for patients, p = 0.01), 
whether a patient was admitted (mean = 3.11 for admitted 
patients versus a mean = 3.91 for those patients 
discharged from the ED, p = 0.034), as well as disease 
severity (mean = 2.83 for  severe disease versus mean = 
3.70 for disease considered as not severe, p = 0.03). These 
results are illustrated in Figure 1. 
 
Most participants responded that their experience in the 
ED was the same during the pandemic as it was before the 
pandemic (n = 45, 78%) (Table 4). The results were 
statistically significant when analyzed by Hgb genotype 
(mean = 3.37 for Hgb SS versus a mean = 3.06 for other 
genotypes, p=0.046) (Figure 1). Most participants stated 
that there was no change in the time it took to get an ED 
bed or to receive medical care (n= 35; 60%) (Table 4). All 
patients reported that they felt the ED personnel took 
proper infectious precautions (n=58; 100%) (Table 4). 
Overall, most participants felt their baseline sickle cell 
disease symptoms were unchanged compared to before 
the pandemic (n= 41; 70%) (Table 4). 
  
All participants were asked if they would answer the 
survey differently at the time that it was administered 
compared to at the beginning of the pandemic (Table 3). 
Five participants responded, and all felt differently about 
their decision to go to the ED. Two participants were 
more worried about returning to ED during the pandemic, 
and three participants were more comfortable going to the 
ED. Twenty-four participants responded to question 9 
about their biggest concern for their ED visit. Most were 
worried about other patients (n=18), followed by the 
waiting area (n = 13), then ED providers (n = 2). All but 2 
of the participants remembered being screened for 
COVID-19 exposure and symptoms (n = 56; 97%). Most 
participants did not choose to utilize telemedicine during 
the pandemic (n = 39; 67%). Many participants 
commented that the wait to see a provider in the ED was 
not longer than usual, but the wait to get a hospital room 
after admission was longer than usual, most likely due to 
the time it took to obtain the results of COVID-19 PCR 
testing.  
 
Figure 1. Responses to Likert Questions 1 through 5, Analyzed by Subgroups 
 
 
Subgroup analysis of response organized by question. 1) My decision to go to the Emergency Room was affected by 
the COVID-19 pandemic. 2) I waited longer before going to the Emergency Room (vs. before pandemic). 3) I tried 
more medications at home for fever and/or pain (vs. before the pandemic). 4) My experience in the Emergency Room 
was better during the pandemic (vs. before the pandemic). 5) I got to a room in the ED and/or got care faster during 





















Q1 Q2 Q3 Q4 Q5
Admitted Discharged from ED Hgb SS
Other Genotype Severe Not Severe
African American Non- African American Parent
Patient
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Discussion 
 
Our results suggest that the COVID-19 pandemic has not 
significantly affected patients’ experience in and 
satisfaction with ED visits or their baseline SCD 
symptoms. Overall, most people felt that the COVID-19 
pandemic affected their decision to go to the Emergency 
Room, which was also notable when analyzed by 
subgroup. Patients with Hgb SS genotype, severe disease, 
patients who were subsequently admitted to the hospital, 
and parents responding to the survey were less affected by 
the pandemic in their decision-making process. One 
possible explanation is that patients who have the Hgb SS 
genotype and severe disease are more likely to have more 
serious and more frequent pain crises. Thus, their decision 
to present to the ED was driven more by their relatively 
worse symptoms, rather than such external factors as the 
pandemic, compared to participants with other genotypes 
and less severe disease. Using admission to the hospital as 
a surrogate for episode severity, it can be argued that 
patients who were having more severe episodes or crises 
were less hesitant to go to the ED. Finally, when 
considering who responded to the survey, recall bias and 
parental concern may account for parents wishing to take 
their children to the Emergency Room regardless of the 
additional risks posed by the COVID-19 pandemic. 
 
Interestingly, most participants did not wait longer than 
usual before going to the ED and took the same amount 
of medication for pain or fever as they usually did during 
the pandemic. Those patients with Hgb SS, severe disease, 
and who self-identified as African American were less 
likely to have waited before going to the ED. In addition, 
those patients with Hgb SS and who self-identified as 
African American were less likely to have taken more 
medication before going to the ED as compared to before 
the pandemic. These subgroups are more likely to have 
more serious and frequent pain crises, which may account 
for the observation that they did not delay in seeking 
medical care. Given the evidence that patients with SCD 
have a much higher risk of significant morbidity and 
mortality if they were to contract SARS-CoV-2 than 
patients without SCD, it is imperative that patients with 
SCD do not defer seeking appropriate, emergent medical 
attention.5 
 
Although there is a substantial level of dissatisfaction with 
ED care that has been well documented among the 
population of patients with SCD, our results indicate that 
the COVID-19 pandemic did not worsen patients’ 
experience or satisfaction with their care.7-8 Most of the 
participants in this study reported that their experience in 
the ED was similar to their ED experiences before the 
pandemic, especially for those with the Hgb SS genotype. 
All respondents reported that the hospital took 
appropriate sanitary and social distancing precautions 
implemented during the pandemic. This result is further 
supported by most respondents not being concerned 
about staying in the waiting room or by the ED providers, 
but expressing concern about the potential risk posed by 
Table 4. Responses to Likert Questions 
 
Question Mean (SD)  
n (%) 
Strongly Disagree  Disagree  Neutral Agree  Strongly Agree  
1 3.43 (1.41) 11 (19%) 3 (5%) 8 (14%) 22 (38%) 14 (24%) 
2 2.52 (1.22) 18(31%) 8 (14%) 17 (29%) 14 (24%) 1(2%) 
3 2.60 (1.25) 16 (28%) 9 (16%) 17 (30%) 12 (21%) 3 (5%) 
4 3.21 (0.59) 0 (0%) 2 (3%) 45 (78%) 8 (14%) 3 (5%) 
5 3.36 (0.77) 0 (0%) 4 (7%) 35 (60%) 13 (23%) 6 (10%) 
6 5.00 (0) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 58 (100%) 
7 3.03 (0.59) 0 (0%) 8 (14%) 41 (70%) 8 (14%) 1 (2%) 
 
1) My decision to go to the Emergency Room was affected by the COVID-19 pandemic.  
2) I waited longer before going to the Emergency Room (vs. before pandemic).  
3) I tried more medications at home for fever and/or pain (vs. before the pandemic).  
4) My experience in the Emergency Room was better during the pandemic (vs. before the pandemic).  
5) I got to a room in the ED and/or got care faster during the pandemic (vs. before the pandemic).  
6) I felt the hospital took the proper infectious precautions (staff wore masks, ER was cleaned regularly, etc.).  
7) I feel like my sickle cell disease symptoms (pain, fever, etc.) are milder now (vs. before the pandemic). 
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other patients. Our results infer that, as most patients did 
not have a more negative experience in the ED during the 
pandemic, they would not be opposed to returning to the 
ED if necessary.  
  
Overall, most participants felt their baseline sickle cell 
disease symptoms were unchanged compared to before 
the pandemic. One theory for the decrease in ED visits by 
patients with SCD during the pandemic is that such 
protective measures such as mask-wearing and social 
distancing result in less spread of viral respiratory illnesses 
in general, thereby leading to fewer SCD exacerbations. 
Our data do not support this theory. Most participants 
stated that there was no change in the time it took to get 
an ED bed or to get medical care. Interestingly, most 
participants did comment on the long wait time to get an 
inpatient bed assigned, most likely due to the time it took 
to run a COVID-19 PCR test per hospital protocol. 
  
There are limitations to the study. The survey was 
conducted with a relatively small sample size of patients 
with SCD who were seen at a single pediatric ED. 
Therefore, care should be taken when generalizing our 
results. There is a risk of recall bias as the survey 
questioned participants about a past ED visit. The study 
was retrospective, as are most survey studies. 
  
Despite the above limitations, this study is meaningful 
given the consistently negative ED encounters historically 
reported by patients with SCD. The results imply that the 
COVID-19 pandemic did not deter those pediatric 
patients with SCD who needed emergency care from 
seeking it, and that their experience and satisfaction with 
the ED was not substantially impacted by the additional 
screening and safety protocols implemented during the 
pandemic. To our knowledge, this is the first study of how 
the COVID-19 pandemic has affected patients’ utilization 
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